Rapamycin may boost brain blood flow in APOE4 carriers, study suggests
A surprising new study suggests that an anti-aging drug could help protect people genetically predisposed to Alzheimer’s disease. The catch: it only worked in people who carry the APOE4 gene variant.
Researchers at the University of Missouri studied whether rapamycin, a medication also investigated for its effects on aging, could affect brain health in people with a genetic predisposition to Alzheimer’s. The study included healthy adults aged 45 to 65, some of whom carried the APOE4 variant, a gene linked to substantially increased Alzheimer’s risk. The findings were published in the Journal of Cerebral Blood Flow & Metabolism.
Why does brain blood flow matter?
APOE4 is a genetic variant that affects how fats are processed in the brain. People who carry it can experience reduced blood flow in certain brain regions years before any memory symptoms appear. That early circulation change is considered a potential warning sign of increased Alzheimer’s risk. All participants received a low daily dose of rapamycin for four weeks. When researchers measured brain blood flow afterward, they found a notable improvement in APOE4 carriers, but not in those without the variant.
Women with APOE4 showed the strongest response
The researchers also found a striking difference between male and female participants. Women carrying APOE4 experienced the largest improvements in brain blood flow. That is particularly relevant because women account for nearly two-thirds of people living with Alzheimer’s disease. The team describes this as an example of precision medicine: identifying who is most likely to respond to a given treatment. This was a pilot study. Whether improved blood flow translates into lower long-term dementia risk has not yet been established, and larger trials are needed.
Want to research this yourself?
Search for example:
- rapamycin cerebral blood flow APOE4 | mTOR inhibition brain aging | precision medicine Alzheimer prevention